CytoDyn (OTCMKTS:CYDY – Get Free Report) posted its quarterly earnings results on Friday. The biotechnology company reported ($0.02) earnings per share for the quarter, Zacks reports.
CytoDyn Stock Down 0.3%
Shares of CYDY stock traded down $0.00 on Friday, reaching $0.28. The stock had a trading volume of 270,772 shares, compared to its average volume of 1,256,880. CytoDyn has a 12 month low of $0.13 and a 12 month high of $0.49. The firm has a market capitalization of $351.90 million, a price-to-earnings ratio of -27.70 and a beta of 1.12. The firm’s 50-day moving average is $0.29 and its two-hundred day moving average is $0.29.
CytoDyn Company Profile
CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.
In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.
Featured Stories
- Five stocks we like better than CytoDyn
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Do not delete, read immediately
- This stock gets a 94 out of 100
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- First Time Since 2007: All Warnings Active
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
